Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 3Sturge-Weber Syndrome 2Neoplasms 2Nausea 2Marijuana Abuse 2Colonic Neoplasms 2Anxiety Disorders 2Vomiting 1Solid Tumor 1Parasomnias 1Pain 1Glioblastoma 1Dysgeusia 1Drug Resistant Epilepsy 1Colorectal Neoplasms 1Cognitive Dysfunction 1Chemotherapy-Induced Peripheral Neuropathy 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Cachexia 1Breast Carcinoma In Situ 1Breast Cancer Female 1Arthralgia 1Appetitive Behavior 1

Interventions

Oxaliplatin 270Bevacizumab 260Fluorouracil 249Irinotecan 240Leucovorin 218Capecitabine 196Cetuximab 161Colonoscopy 74Folfox protocol 70Panitumumab 64regorafenib 62Drug Therapy 52Radiotherapy 50HMPL-013 50Blood Specimen Collection 45trifluridine tipiracil drug combination 43pembrolizumab 41Surveys and Questionnaires 35Standard of Care 35Nivolumab 34Neoadjuvant Therapy 34Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 31IFL protocol 27Trifluridine 26Interviews as Topic 26Celecoxib 26XELOX 25Early Intervention, Educational 24Specimen Handling 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Colorectal Neoplasms × Cannabidiol × Clear all
NCT07167446 2025-10-22

Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

Fox Chase Cancer Center

Phase EARLY_PHASE1 Recruiting
30 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡